pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

3,983 catalysts · 4,728 grant · 3,869 device 510k · 3,350 8k filing · 3,052 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 0 catalysts2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: recall×type: approval×from 2025-01-31×clear all
type
  • grant4,728
  • device 510k3,869
  • 8k filing3,350
  • approval3,052
  • device pma2,000
  • device recall2,000
device adverse event
1,000
  • recall931
  • earnings584
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Jan 27, 2025

    5
    ›Jan 31, 2025approval561d agoSOGROYA (SOMAPACITAN-BECO) — FDA approvalsomatriptan albumin bound LA

    Sponsor: NOVO NORDISK INC. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →somatriptan albumin bound LA →fda approvals ↗
    ›Jan 31, 2025approval561d agoPAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approvalPAXLOVID (COPACKAGED)

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →PAXLOVID (COPACKAGED) →fda approvals ↗
    ›Jan 31, 2025approval561d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Jan 31, 2025approval561d agoUNASYN (AMPICILLIN SODIUM) — FDA approvalUNASYN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →UNASYN →fda approvals ↗
    ›Jan 31, 2025approval561d agoPEPCID COMPLETE (CALCIUM CARBONATE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: TABLET, CHEWABLE. Route: ORAL

    full page →fda approvals ↗

    Week of Feb 3, 2025

    14
    ›Feb 3, 2025approval558d agoVALPROIC ACID — FDA approvalCereno Scientific AB

    Sponsor: CHARTWELL RX. Form: SYRUP. Route: ORAL

    full page →fda approvals ↗
    ›Feb 4, 2025approval

    Week of Feb 10, 2025

    28
    ›Feb 10, 2025approval551d agoENZEEVU (AFLIBERCEPT-ABZV) — FDA approvalaflibercept biosimilar

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →aflibercept biosimilar →fda approvals ↗
    ›Feb 11, 2025approval

    Week of Feb 17, 2025

    3
    ›Feb 18, 2025approval543d agoATROPINE SULFATE — FDA approvalATROPINE SULFATE

    Sponsor: ACCORD HLTHCARE. Form: SOLUTION. Route: INTRAVENOUS

    full page →ATROPINE SULFATE →fda approvals ↗
    ›Feb 18, 2025approval
    ← prev
    page 1 of 80
    next →
    557d ago
    GABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Feb 4, 2025approval557d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Feb 5, 2025approval556d agoBOSENTAN — FDA approvalBOSENTAN

    Sponsor: NATCO PHARMA LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →BOSENTAN →fda approvals ↗
    ›Feb 5, 2025approval556d agoRIFATER (ISONIAZID) — FDA approvalRIFATER

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →RIFATER →fda approvals ↗
    ›Feb 5, 2025approval556d agoWELLBUTRIN (BUPROPION HYDROCHLORIDE) — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Feb 5, 2025recall556d agoThe W.S. Badger Company, Inc. recall (Cls III)

    BADGER 50, ADVENTURE SPORT MINERAL SUNSCREEN WITH CLEAR ZINC, (uncoated 25% zinc oxide), 2.4 oz., Tin, W.S. Badger Company, Inc, 768 Route 10, Gilsum NH, 03448 UPC 6 34084 47150 2 — Reason: Labeling: Missing Label: The finished product potentially missing the labeling with the drug facts panel, bar code and directions for use. — Status: Terminated

    full page →fda recalls ↗
    ›Feb 5, 2025recall556d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)

    Duloxetine Delayed-Release Capsules USP, 20 mg, packaged in a) 30 Unit Doses (3x10 blister packs) NDC 0904-7043-04 and b) 100 Unit Doses (10x10 blister packs) NDC 0904-7043-61, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA. — Reason: CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit — Status: Terminated

    full page →fda recalls ↗
    ›Feb 5, 2025recall556d agoAstellas Pharma US Inc. recall (Cls I)Astellas Pharma US Inc

    Prograf (tacrolimus) capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Product of Japan, Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062, NDC 0469-0607-73. — Reason: Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 5, 2025recall556d agoMcKesson recall (Cls II)MCKESSON CORP

    Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01 — Reason: cGMP Deviations: Product intended for quarantine was inadvertently distributed. — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 5, 2025recall556d agoAstellas Pharma US Inc. recall (Cls I)Astellas Pharma US Inc

    Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73. — Reason: Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 6, 2025approval555d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: KINDOS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 7, 2025approval554d agoZEPBOUND (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗
    ›Feb 7, 2025approval554d agoONGENTYS (OPICAPONE) — FDA approvalopicapone

    Sponsor: AMNEAL. Form: CAPSULE. Route: ORAL

    full page →opicapone →fda approvals ↗
    550d ago
    CAMCEVI KIT (LEUPROLIDE MESYLATE) — FDA approvalForesee Pharmaceuticals Co Ltd

    Sponsor: ACCORD. Form: EMULSION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Feb 11, 2025approval550d agoEVRYSDI (RISDIPLAM) — FDA approvalEVRYSDI

    Sponsor: GENENTECH INC. Form: TABLET. Route: ORAL

    full page →EVRYSDI →fda approvals ↗
    ›Feb 11, 2025approval550d agoEVRYSDI (RISDIPLAM) — FDA approvalEVRYSDI

    Sponsor: GENENTECH INC. Form: FOR SOLUTION. Route: ORAL

    full page →EVRYSDI →fda approvals ↗
    ›Feb 11, 2025approval550d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: RHODES PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Feb 11, 2025approval550d agoPEPCID COMPLETE (CALCIUM CARBONATE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: TABLET, CHEWABLE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 12, 2025approval549d agoMETHYLPREDNISOLONE ACETATE — FDA approvalMETHYLPREDNISOLONE ACETATE

    Sponsor: SANDOZ. Form: INJECTABLE. Route: INJECTION

    full page →METHYLPREDNISOLONE ACETATE →fda approvals ↗
    ›Feb 12, 2025approval549d agoMETHYLPREDNISOLONE ACETATE — FDA approvalMETHYLPREDNISOLONE ACETATE

    Sponsor: SANDOZ. Form: INJECTABLE. Route: INJECTION

    full page →METHYLPREDNISOLONE ACETATE →fda approvals ↗
    ›Feb 12, 2025approval549d agoIZERVAY (AVACINCAPTAD PEGOL SODIUM) — FDA approvalavacincaptad pegol sodium

    Sponsor: ASTELLAS. Form: SOLUTION. Route: INTRAVITREAL

    full page →avacincaptad pegol sodium →fda approvals ↗
    ›Feb 12, 2025approval549d agoPAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approvalPAXLOVID (COPACKAGED)

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →PAXLOVID (COPACKAGED) →fda approvals ↗
    ›Feb 12, 2025approval549d agoSELARSDI (USTEKINUMAB-AEKN) — FDA approvalAlvotech

    Sponsor: ALVOTECH USA INC. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 12, 2025approval549d agoVICTOZA (LIRAGLUTIDE) — FDA approvalSaxenda

    Sponsor: NOVO NORDISK INC. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →Saxenda →fda approvals ↗
    ›Feb 12, 2025approval549d agoACETYLCYSTEINE — FDA approvalACETYLCYSTEINE

    Sponsor: SOMERSET THERAPS LLC. Form: SOLUTION. Route: INHALATION, ORAL

    full page →ACETYLCYSTEINE →fda approvals ↗
    ›Feb 12, 2025recall549d agoRemedyRepack Inc. recall (Cls II)RemedyRepack Inc

    Carvedilol 25 mg Tablet, QTY: 30 Tablets per Blister Pack (3 x 10 blister cards), Rx Only, MFG by: Glenmark, Mahwah, NJ 07430, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC: 70518-3945-00. — Reason: CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit. — Status: Terminated

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoPAI Holdings, LLC. dba Pharmaceutical Associates Inc recall (Cls III)Cosette Pharmaceuticals Inc

    Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc., Greenville, SC 29605, NDC 0121-0775-16 — Reason: Superpotent; sodium benzoate preservative — Status: Completed

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Carvedilol Tablets, USP, 12.5 mg, Rx only, a)500 Tablets, NDC 68462-164-05; b) 100 Tablets, NDC 68462-164-01, Manufactured for Glenmark Pharmaceuticals, NJ. — Reason: CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Carvedilol Tablets, USP, 25 mg, Rx only, a)500 Tablets, NDC 68462-165-05; b) 100 Tablets, NDC 68462-165-01, Manufactured for Glenmark Pharmaceuticals, NJ. — Reason: CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)Aurobindo Pharma USA Inc

    Potassium Chloride Extended-Release Tablets, USP, 10 mEq (750 mg), 100 Tablets per carton (10 x 10 unit dose blisters), Rx Only, Distributed by: Aurobindo Pharma USA< INC., 279 Princeton-Hightstown Road, East Windsor, NJ 08520. Made in India. Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152. NDC: 0904-7216-61 — Reason: Failed Dissolution Specifications. — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

    Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel. — Reason: Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoENDO USA, Inc. recall (Cls I)Par Pharmaceutical Inc

    Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP), 30mg/30mL (1mg/mL), packaged in 30 mL vials, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-103-01 — Reason: Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP) — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoSKY PACKAGING recall (Cls II)Strides Pharma Science Ltd

    HydrALAZINE Hydrochloride, 100 Tablets (10x10), USP, 50mg, Rx only, Manufactured by Strides Pharma Science Ltd, Bengaluru, India, Distributed by McKesson by: McKesson Corporation dba SKY Packaging, TN 38141. NDC 63739-328-10 — Reason: Failed Impurities/Degradation Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoSKY PACKAGING recall (Cls II)Strides Pharma Science Ltd

    HydrALAZINE Hydrochloride, 25 mg, 100 Unit Dose Tablets (10x10), USP, Rx only, Manufactured by Strides Pharma Science Ltd, Bengaluru, India, Distributed by McKesson by: McKesson Corporation dba SKY Packaging, TN 38141. NDC 63739-327-10 — Reason: Failed Impurities/Degradation Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 12, 2025recall549d agoFDC Limited recall (Cls II)FDC Ltd

    Timolol Maleate Ophthalmic Solution USP, 0.5%, Sterile, 5mL bottles, Rx only, Manufactured by: FDC Limited, Waluj, Aurangabad, Maharashtra, India, Distributed by: Rising Pharmaceuticals Inc, New Jersey, NDC 64980-514-05. — Reason: Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle. — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 13, 2025approval548d agoTRUQAP (CAPIVASERTIB) — FDA approvalcapivasertib

    Sponsor: ASTRAZENECA. Form: TABLET. Route: ORAL

    full page →capivasertib →fda approvals ↗
    ›Feb 13, 2025approval548d agoDENOSUMAB-DSSB — FDA approvaldenosumab biosimilar

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →denosumab biosimilar →fda approvals ↗
    ›Feb 14, 2025approval547d agoROMVIMZA (VIMSELTINIB) — FDA approvalDeciphera Pharmaceuticals Inc

    Sponsor: DECIPHERA PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 14, 2025approval547d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →amivantamab →fda approvals ↗
    ›Feb 14, 2025approval547d agoSIMLANDI (ADALIMUMAB-RYVK) — FDA approvalAlvotech

    Sponsor: ALVOTECH USA INC. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    543d ago
    LORBRENA (LORLATINIB) — FDA approvallorlatinib

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →lorlatinib →fda approvals ↗
    ›Feb 19, 2025approval542d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    $PFE26.79-0.04%
    $NVO45.89-1.78%
    $KVUE19.200.00%
    $PFE26.79-0.04%
    $NSRX2.7000-1.82%
    $AMRX18.15+5.10%
    $LLY1180.16-2.25%
    $MCK869.00+1.44%
    $IGC0.2670+0.41%
    $ALVO4.0550-0.86%
    $NVO45.89-1.78%
    $PFE26.79-0.04%
    $KVUE19.200.00%
    $LBRX47.77+7.92%
    $LBRX47.77+7.92%
    $TERN52.95-0.03%
    $AZN156.45-0.50%
    $PFE26.79-0.04%
    $ALVO4.0550-0.86%